230 related articles for article (PubMed ID: 20149240)
1. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.
Kim BH; Jee JG; Yin CH; Sandoval C; Jayabose S; Kitamura D; Bach EA; Baeg GH
Mol Cancer; 2010 Feb; 9():36. PubMed ID: 20149240
[TBL] [Abstract][Full Text] [Related]
2. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
Kim BH; Yi EH; Jee JG; Jeong AJ; Sandoval C; Park IC; Baeg GH; Ye SK
J Cell Mol Med; 2020 Jul; 24(13):7427-7438. PubMed ID: 32558259
[TBL] [Abstract][Full Text] [Related]
3. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity.
Kim BH; Oh SR; Yin CH; Lee S; Kim EA; Kim MS; Sandoval C; Jayabose S; Bach EA; Lee HK; Baeg GH
Br J Haematol; 2010 Jan; 148(1):132-43. PubMed ID: 19793252
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.
Kim BH; Yin CH; Guo Q; Bach EA; Lee H; Sandoval C; Jayabose S; Ulaczyk-Lesanko A; Hall DG; Baeg GH
Mol Cancer Ther; 2008 Sep; 7(9):2672-80. PubMed ID: 18790749
[TBL] [Abstract][Full Text] [Related]
5. Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors.
Yin CH; Bach EA; Baeg GH
J Biomol Screen; 2011 Apr; 16(4):443-9. PubMed ID: 21393628
[TBL] [Abstract][Full Text] [Related]
6. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.
Kim BH; Min YS; Choi JS; Baeg GH; Kim YS; Shin JW; Kim TY; Ye SK
Exp Mol Med; 2011 May; 43(5):313-21. PubMed ID: 21499010
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.
Kim BH; Kim M; Yin CH; Jee JG; Sandoval C; Lee H; Bach EA; Hahm DH; Baeg GH
Br J Pharmacol; 2011 Sep; 164(1):106-18. PubMed ID: 21434883
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways.
Nagy ZS; Ross JA; Rodriguez G; Bader J; Dimmock J; Kirken RA
FEBS Lett; 2010 Apr; 584(8):1515-20. PubMed ID: 20211620
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
10. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
11. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
12. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex.
Rodriguez G; Ross JA; Nagy ZS; Kirken RA
J Biol Chem; 2013 Mar; 288(10):7137-46. PubMed ID: 23341462
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
15. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
17. Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors.
Uckun FM; Vassilev A; Dibirdik I; Tibbles H
Anticancer Agents Med Chem; 2007 Nov; 7(6):612-23. PubMed ID: 18045056
[TBL] [Abstract][Full Text] [Related]
18. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
Zhang LL; Pan HX; Wang YX; Guo T; Liu L
Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation.
Ross JA; Cheng H; Nagy ZS; Frost JA; Kirken RA
J Biol Chem; 2010 Feb; 285(6):3582-3591. PubMed ID: 19923221
[TBL] [Abstract][Full Text] [Related]
20. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
